

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)



(10) International Publication Number
WO 2021/262962 A1

(51) International Patent Classification:

A61K 31/4178 (2006.01) A61K 31/454 (2006.01)
A61K 31/4184 (2006.01) A61K 31/519 (2006.01)
A61K 31/4535 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2021/038870

(22) International Filing Date:

24 June 2021 (24.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/044,127 25 June 2020 (25.06.2020) US

(71) Applicant: **CELGENE CORPORATION** [US/US]; 86
Morris Avenue, Summit, NJ 07901 (US).

(72) Inventors: **AHSAN, Aarif**; Celgene Summit West, 556
Morris Avenue, Summit, NJ 07901 (US). **BISHT, Kam-
lesh**; 38 Newell Street, Hillsborough Township, NJ 08844
(US). **BJORKLUND, Chad**; Celgene Summit West, 556
Morris Avenue, Summit, NJ 07901 (US). **FLYNT, Jen-
nifer, Erin**; Celgene Summit West, 556 Morris Av-
enue, Summit, NJ 07901 (US). **HISU, Chih-chao**; Cel-
gene Summit West, 556 Morris Avenue, Summit, NJ
017901 (US). **JEYARAJU, Danny, Vijey**; Celgene Sum-
mit West, 556 Morris Avenue, Summit, NJ 07901 (US).

ORTIZ-ESTEVEZ, Maria; Calls Isaac Newton, 4-planta
2, Pabellon De Italia, 41092 Isla De La Cartuja, Sevilla (ES).
PIERCEALL, William, Edward; Celgene Summit West,
556 Morris Avenue, Summit, NJ 07901 (US). **THAKUR-
TA, Anjan**; Celgene Summit West, 556 Morris Avenue,
Summit, NJ 07901 (US). **TOWFIC, Fadi, George**; 10300
Campus Point Drive, Suite 100, San Diego, CA 92121 (US).

(74) Agent: **BRUNER, Michael, J.** et al.; Jones Day, 250 Vesey
Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES




Figure 1A

(57) Abstract: Provided herein are methods of using a compound provided herein (e.g., Compound 1, Compound 2, Compound 3, Compound 4, Compound 5, Compound 6, or Compound 7, or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof), in combination with a second active agent for treating cancer. The second active agent is one or more of a PLK1 inhibitor, a BRD4 inhibitor, a BET inhibitor, an NEK2 inhibitor, an AURKB inhibitor, a MEK inhibitor, a PHF19 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a DOT1L inhibitor, an EZH2 inhibitor, a JAK2 inhibitor, a BIRC5 inhibitor, or a DNA methyltransferase inhibitor.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*